|
(11) | EP 3 489 238 B8 |
| (12) | CORRECTED EUROPEAN PATENT SPECIFICATION |
| Note: Bibliography reflects the latest situation |
|
|
| (54) |
PHARMACEUTICAL COMPOSITIONS OF 6H-PYRIDO[3,2-E][1,2,4]TRIAZOLO[1,5-C]PYRIMIDIN-5-ONE AND [1,2,4]TRIAZOLO[1,5-C]PTERIDIN-5(6H)-ONE DERIVATIVES AS PDE1 INHIBITORS FOR TREATING E.G. NEUROLOGICAL DISORDERS PHARMAZEUTISCHE ZUSAMMENSETZUNGEN VON 6H-PYRIDO[3,2-E][1,2,4]TRIAZOLO[1,5-C]PYRIMIDIN-5-ON- UND [1,2,4]TRIAZOLO[1,5-C]PTERIDIN-5(6H)-ON-DERIVATEN ALS PDE1 INHIBITOREN ZUR BEHANDLUNG VON NEUROLOGISCHEN STÖRUNGEN COMPOSITIONS PHARMACEUTIQUES DE DÉRIVÉS DE 6-BENZYL-6H-PYRIDO[3,2-E][1,2,4]TRIAZOLO[1,5-C]PYRIMIDIN-5-ONE ET 6-BENZYL-[1,2,4]TRIAZOLO[1,5-C]PTERIDIN-5(6H)-ONE EN TANT QU'INHIBITEURS DE PDE1 INHIBITORS POUR LE TRAITEMENT DES TROUBLES NEUROLOGIQUES |
|
|
|||||||||||||||||||||||||||||||||||
| Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention). |